Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › insulin degludec/insulin aspart

insulin degludec/insulin aspart

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of insulin degludec/insulin aspart

18 trials tracked of insulin degludec/insulin aspart: 15 in phase 3 or 4 and 3 with published results. The most-cited published study has 40 citations.

18Trials tracked
15Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 15 Phase 2 3
  1. Phase 3 A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification Completed · 40 cited
  2. Phase 3 Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan Completed · 39 cited
  3. Phase 3 Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes Completed · 28 cited
  4. Phase 3 A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes Completed
  5. Phase 3 Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens Completed
  6. Phase 3 Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes Completed
Show 12 more trials
  1. Phase 3 A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily Completed
  2. Phase 3 Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes Completed
  3. Phase 3 Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine Completed
  4. Phase 3 A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus Completed
  5. Phase 3 Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes Completed
  6. Phase 3 Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes Completed
  7. Phase 3 Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes Completed
  8. Phase 3 A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes Completed
  9. Phase 3 A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin Completed
  10. Phase 2 Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes Completed
  11. Phase 2 Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus Completed
  12. Phase 2 Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4%
Nutrition & Obesity Medicine Sys. Review
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4% Comparing Combination Diabetes Drugs for Blood Sugar Control
This network meta-analysis evaluated 12,815 patients with type 2 diabetes to compare fixed-ratio combination products and their individual c…
A review of 12,815 patients found that insulin degludec/liraglutide may be best for lowering blood sugar, but has more side effects than oth…
Jun 4, 2026